Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 1Multiple Myeloma 1

Interventions

Dexamethasone 20daratumumab 17Bortezomib 12Lenalidomide 11pomalidomide 8Cyclophosphamide 8Calcium Dobesilate 7belantamab mafodotin 5isatuximab 4fludarabine 4carfilzomib 4Melphalan 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Biopsy 3tocilizumab 2iberdomide 2Stem Cell Transplantation 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Rivaroxaban × Plasma cell × Clear all
NCT06580223 2025-07-18

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Not yet recruiting
530 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡